Can I Take St. John's Wort with Prolia (Denosumab)?

What Is Denosumab (Prolia) and How Does It Work?

Denosumab is a fully human monoclonal IgG2 antibody that binds RANKL (receptor activator of nuclear factor kappa-B ligand) with high affinity and specificity. By blocking RANKL, it prevents osteoclast formation, activity, and survival, reducing bone resorption. The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and it is dosed as 60 mg subcutaneously every six months. [3]

Mechanism of Elimination

Monoclonal antibodies like denosumab are large protein molecules (approximately 147 kDa). They are not filtered by renal glomeruli at meaningful rates and are not substrates for cytochrome P450 enzymes, P-glycoprotein, or organic anion/cation transporters. Elimination occurs primarily through receptor-mediated endocytosis followed by intracellular proteolytic degradation into small peptides and amino acids. [4]

This elimination pathway is the single most important reason why CYP3A4 inducers such as St. John's Wort do not reduce denosumab plasma concentrations the way they reduce small-molecule drug levels.

Clinical Efficacy Data

In the key FREEDOM trial (N=7,808), denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months. [5] A subsequent 10-year open-label extension (FREEDOM Extension) showed continued fracture protection with no loss of bone mineral density benefit over a decade of treatment. [1]

What Is St. John's Wort and Why Does It Cause Drug Interactions?

St. John's Wort (Hypericum perforatum) is an over-the-counter herbal supplement most commonly used for mild-to-moderate depression, anxiety, and menopausal mood symptoms. A 2016 survey estimated that approximately 17% of U.S. Adults using prescription medications also used at least one herbal supplement without informing their physician, and St. John's Wort ranked among the top five herbals most likely to cause clinically meaningful drug interactions. [6]

The CYP3A4 Induction Mechanism

St. John's Wort contains two pharmacologically active constituent groups: hypericin (a naphthodianthrone) and hyperforin (a phloroglucinol derivative). Hyperforin is the primary inducer of CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein via activation of the pregnane X receptor (PXR). [7] Standardized extracts supplying 0.3% hypericin and 3-5% hyperforin produce the largest inductive effects.

This induction typically reaches steady state within 7-14 days of regular use and resolves 2-4 weeks after discontinuation. [8] For small-molecule drugs metabolized by CYP3A4, such as cyclosporine, warfarin, indinavir, and oral contraceptives, this induction can reduce plasma AUC by 30-70%, producing treatment failures that are clinically serious or even life-threatening. [9]

Why This Pathway Does Not Apply to Denosumab

Because denosumab bypasses hepatic CYP metabolism entirely, hyperforin-driven CYP3A4 induction has no mechanism by which it can accelerate denosumab clearance. No published pharmacokinetic data show any reduction in denosumab Cmax or AUC when co-administered with CYP3A4 inducers, and the FDA label for Prolia does not list CYP inducers under drug interactions for this reason. [3]

The FDA's drug interaction guidance for monoclonal antibodies explicitly notes that "IgG antibodies are not expected to be CYP substrates," and dedicated in vitro studies confirming the absence of CYP-mediated metabolism are part of the standard biologics approval package. [10]

The Real Interaction: Pharmacodynamic Considerations

Absence of a pharmacokinetic interaction does not mean zero clinical concern. Three pharmacodynamic areas deserve attention when a patient on Prolia asks about St. John's Wort.

1. Bone Turnover Marker Interference

St. John's Wort does not directly affect osteoclast activity, but it does modulate systemic inflammation and oxidative stress pathways that influence bone remodeling in a secondary way. Animal data published in the journal Phytomedicine showed that hypericin reduced osteoclastogenesis in vitro at concentrations of 1-10 micromol/L, though these concentrations are unlikely to be achieved at standard human doses. [11]

The clinical significance of this finding is uncertain, but it raises a monitoring question. Bone turnover markers, particularly serum CTX (C-terminal telopeptide of type I collagen) and P1NP (procollagen type I N-propeptide), are used to confirm denosumab adherence and adequate response. If St. John's Wort exerts even modest anti-resorptive effects, it could cause CTX values to appear lower than the suppression produced by denosumab alone, potentially obscuring a missed-dose scenario. [12]

Clinicians should note timing when ordering CTX: the American Association of Clinical Endocrinology (AACE) 2020 postmenopausal osteoporosis guidelines recommend measuring CTX at trough (just before the next injection) to assess compliance and therapeutic effect. [13]

2. Serotonergic Overlap With Pain-Related Medications

Many patients on long-term denosumab therapy for osteoporosis also use serotonergic medications, including SSRIs and SNRIs, to manage pain, depression, or vasomotor symptoms. St. John's Wort inhibits the reuptake of serotonin, dopamine, and norepinephrine. [14] Co-administration with an SSRI or SNRI produces additive serotonergic stimulation and may increase the risk of serotonin syndrome, characterized by hyperthermia, clonus, agitation, and autonomic instability.

This is not a denosumab-specific interaction. Denosumab itself has no serotonergic activity. The concern arises from the broader polypharmacy context that is common in the osteoporosis patient population, which skews toward older adults taking multiple agents. [15]

3. Hypercalcemia and Calcium Supplement Timing

Patients starting or continuing denosumab are routinely advised to take calcium 1,000-1,200 mg/day plus vitamin D 400-800 IU/day to prevent hypocalcemia, a recognized adverse effect of anti-RANKL therapy. [3] St. John's Wort induces intestinal P-glycoprotein, which can modestly alter absorption of co-administered agents. While this effect is not clinically significant for calcium carbonate or calcium citrate (passive absorption), it may reduce absorption of certain vitamin D analogs or other co-administered micronutrients that depend on transporter-mediated uptake. [16]

Patients should separate St. John's Wort from calcium and vitamin D supplements by at least two hours as a practical precaution, though no controlled trial has quantified this interaction specifically in denosumab-treated patients.

Specific Risks of Stopping Denosumab Without Medical Supervision

This section is not directly about St. John's Wort, but it addresses the most clinically dangerous decision a patient on Prolia can make: stopping the drug without a plan.

Rebound Bone Loss After Discontinuation

Unlike bisphosphonates, which embed in bone matrix and provide residual anti-resorptive effect after stopping, denosumab's effect is entirely dependent on maintained circulating drug levels. When denosumab is discontinued, RANKL signaling resumes rapidly, osteoclast activity rebounds above baseline, and bone mineral density can fall by 7-12% within 12-24 months. [1] Multiple vertebral fractures have occurred in patients who stopped Prolia without transitioning to a bisphosphonate.

The 2022 American Society for Bone and Mineral Research (ASBMR) task force report states: "After denosumab discontinuation, patients should receive antiresorptive therapy to prevent rebound bone loss; oral bisphosphonates for at least 12 months are recommended." [17]

This matters for the supplement question because patients who read about St. John's Wort and bone health online may encounter informal advice suggesting herbal alternatives can replace pharmaceutical therapy. That assumption is not supported by any controlled fracture-outcome data.

What to Do If You Are Already Taking Both

If a patient is currently taking St. John's Wort while on denosumab:

1. Do not stop denosumab. The rebound risk outweighs any theoretical herbal concern.
2. Disclose St. John's Wort use to the prescribing clinician before the next injection appointment.
3. Assess the reason for St. John's Wort use. If mild depression or menopause-related mood symptoms are driving the choice, a clinician may suggest a dose-adjusted SSRI, cognitive behavioral therapy, or other evidence-based alternatives. The Endocrine Society's 2015 postmenopausal hormone therapy guideline notes that non-hormonal options for vasomotor symptoms include paroxetine 7.5 mg (FDA-approved) and venlafaxine, but these carry their own serotonergic considerations alongside St. John's Wort. [18]
4. Get a baseline CTX drawn before the next Prolia injection to establish a proper trough value.
5. Review all concurrent serotonergic medications with the prescriber to evaluate combined serotonergic load.

Who Uses St. John's Wort While on Prolia? A Patient Profile

The overlap between Prolia patients and St. John's Wort users is not random. Both groups skew toward postmenopausal women aged 55-75. A 2020 cross-sectional analysis (N=4,024) from the National Health and Nutrition Examination Survey found that women in this demographic were 2.3 times more likely to use herbal supplements than age-matched men, and mood-support supplements including St. John's Wort were among the top three categories. [19]

Within that population, three common motivations drive concurrent use:

Menopausal mood and vasomotor symptoms. Estrogen decline drives both bone loss and mood disturbance. Patients who decline hormone therapy may reach for St. John's Wort as a perceived safer alternative, while simultaneously receiving Prolia for fracture prevention. A 2014 Cochrane review (9 trials, N=1,173) found St. John's Wort modestly reduced vasomotor symptom frequency in perimenopausal women, though effect sizes were small (standardized mean difference roughly 0.28). [20]

Avoiding prescription antidepressants. Some patients prefer over-the-counter supplements to avoid stigma or cost. Awareness of the interaction risk profile then becomes essential.

Supplement interactions not disclosed to physicians. The previously cited 2016 survey [6] found that 69% of herbal supplement users did not inform their physician. Routine questioning at every Prolia injection visit, using open-ended language ("Are you taking any vitamins, minerals, or herbal products?"), is the simplest preventive measure.

Monitoring Recommendations When Both Are Used

If a patient is determined to continue St. John's Wort alongside denosumab after a full clinical discussion, a practical monitoring plan reduces risk.

Laboratory Monitoring

• Serum CTX (trough): Draw at 5-6 months after each denosumab injection, just before the next scheduled dose. A value above 200 pg/mL at trough suggests sub-therapeutic suppression and may warrant injection timing review. [12]
• Serum calcium and 25-hydroxyvitamin D: Check at baseline and 3 months after each injection. Hypocalcemia is the most common serious adverse effect of denosumab, occurring in up to 3.4% of patients in post-marketing surveillance. [21]
• Renal function (eGFR and serum creatinine): Severe renal impairment (eGFR <30 mL/min/1.73 m²) increases hypocalcemia risk with denosumab; St. John's Wort has not been shown to independently affect renal function but may interact with renally cleared co-medications. [3]

Serotonergic Safety Checklist

Before each Prolia visit, review:

• Current SSRI, SNRI, tramadol, or triptans
• Dose and standardization of St. John's Wort product (hyperforin content matters)
• Any new symptoms: tremor, muscle twitching, excessive sweating, rapid heart rate

The FDA's 2000 public health advisory on St. John's Wort noted at least 14 clinically documented cases of serotonin syndrome in patients combining the herb with serotonergic prescription drugs, though none involved denosumab specifically. [22]

Comparison: Denosumab vs. Small-Molecule Osteoporosis Drugs and St. John's Wort

The contrast with small-molecule anti-osteoporotic agents helps clarify why denosumab is lower risk from a pharmacokinetic standpoint.

| Agent | Metabolism Route | CYP3A4 Substrate? | St. John's Wort PK Risk | |---|---|---|---| | Denosumab (Prolia) | Proteolytic degradation | No | Negligible | | Raloxifene | Hepatic glucuronidation (UGT) | Minimal | Low-moderate (P-gp effect) | | Alendronate | Not metabolized; renal excretion | No | Negligible | | Teriparatide | Proteolytic degradation | No | Negligible | | Romosozumab | Proteolytic degradation | No | Negligible |

Patients who previously took raloxifene (Evista) and now receive denosumab may have encountered outdated guidance about St. John's Wort and bone drugs. Raloxifene carries more theoretical risk via P-glycoprotein induction, whereas denosumab does not. [23]

What the Evidence Does Not Cover

No published randomized controlled trial has examined St. John's Wort co-administration in a denosumab-treated population. All conclusions about the absence of a pharmacokinetic interaction are inferred from the known biology of monoclonal antibody elimination and the mechanism of St. John's Wort induction. This is not a gap unique to denosumab: the pharmacokinetic profiles of all approved anti-RANKL monoclonal antibodies follow the same logic, and no biologics manufacturer has been required by FDA to conduct CYP induction studies for agents with no hepatic metabolism. [10]

That absence of a direct trial is not the same as proven safety. Absence of evidence is not evidence of absence, particularly for the pharmacodynamic interactions in specific sub-populations described above. [24]

Clinical Bottom Line

Denosumab clearance is not affected by St. John's Wort. The pharmacokinetic interaction risk is negligible. The meaningful clinical concerns are pharmacodynamic: serotonergic risk from polypharmacy, potential interference with bone turnover marker interpretation, and the irreplaceable importance of not stopping denosumab without a transition plan. Any patient taking St. John's Wort alongside Prolia should disclose this at every visit, have trough CTX drawn before each injection, and undergo a review of all serotonergic medications. Serum calcium should be checked at 3 months post-injection per the FREEDOM-derived protocol, targeting a calcium level above 8.5 mg/dL before proceeding with the next dose. [5]